Manish Monga

7.6k total citations
37 papers, 1.0k citations indexed

About

Manish Monga is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Manish Monga has authored 37 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Manish Monga's work include Cancer Immunotherapy and Biomarkers (13 papers), Head and Neck Cancer Studies (7 papers) and Fibroblast Growth Factor Research (5 papers). Manish Monga is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Head and Neck Cancer Studies (7 papers) and Fibroblast Growth Factor Research (5 papers). Manish Monga collaborates with scholars based in United States, Italy and France. Manish Monga's co-authors include Yusri Elsayed, Edward A. Sausville, Jane B. Trepel, Giovanni Melillo, Eun Joo Chung, William D. Figg, Donna Headlee, James A. Zwiebel, Kyunghwa Hwang and Qin Ryan and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Manish Monga

35 papers receiving 981 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manish Monga United States	13	582	478	158	124	86	37	1.0k
Justine Y. Bruce United States	16	413 0.7×	329 0.7×	275 1.7×	71 0.6×	81 0.9×	73	955
Zizhen Feng China	12	671 1.2×	272 0.6×	140 0.9×	137 1.1×	37 0.4×	23	1.0k
Mariko Mihara Japan	21	745 1.3×	674 1.4×	203 1.3×	125 1.0×	209 2.4×	38	1.3k
Jin‐Hyuk Choi South Korea	18	318 0.5×	488 1.0×	483 3.1×	126 1.0×	75 0.9×	73	944
M.J. Millward Australia	13	403 0.7×	580 1.2×	340 2.2×	54 0.4×	34 0.4×	31	842
Derek B. Allison United States	19	290 0.5×	302 0.6×	214 1.4×	258 2.1×	64 0.7×	91	895
Shilpi Arora United States	15	680 1.2×	260 0.5×	98 0.6×	56 0.5×	41 0.5×	31	948
Vincent J. Bakanauskas United States	8	685 1.2×	428 0.9×	230 1.5×	58 0.5×	59 0.7×	8	975
A. D. Colevas United States	10	355 0.6×	391 0.8×	113 0.7×	35 0.3×	27 0.3×	24	652

Countries citing papers authored by Manish Monga

Since Specialization

Citations

This map shows the geographic impact of Manish Monga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manish Monga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manish Monga more than expected).

Fields of papers citing papers by Manish Monga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manish Monga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manish Monga. The network helps show where Manish Monga may publish in the future.

Co-authorship network of co-authors of Manish Monga

This figure shows the co-authorship network connecting the top 25 collaborators of Manish Monga. A scholar is included among the top collaborators of Manish Monga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manish Monga. Manish Monga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Choueiri, Toni K., Jae‐Lyun Lee, Jaime R. Merchan, et al.. (2025). Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.. Journal of Clinical Oncology. 43(5_suppl). 441–441.

Siefker‐Radtke, Arlene O., Andrea Necchi, Se Hoon Park, et al.. (2021). Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 39(6_suppl). 426–426. 1 indexed citations

Breyer, Johannes, Manish Monga, Roman Mayr, et al.. (2020). 758P Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC). Annals of Oncology. 31. S587–S588. 1 indexed citations

Rezazadeh, Arash, Yohann Loriot, Arlene O. Siefker‐Radtke, et al.. (2020). 757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status. Annals of Oncology. 31. S586–S587. 5 indexed citations

Park, Joon Oh, Yin‐Hsun Feng, Yen‐Yang Chen, et al.. (2019). Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.. Journal of Clinical Oncology. 37(15_suppl). 4117–4117. 63 indexed citations

Licitra, Lisa, Robert L. Ferris, George R. Blumenschein, et al.. (2017). Nivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141. Annals of Oncology. 28. v377–v378. 3 indexed citations

Haddad, Robert I., George R. Blumenschein, Jérôme Fayette, et al.. (2017). Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes. Annals of Oncology. 28. v372–v373. 31 indexed citations

Ferris, Robert L., Lisa Licitra, Jérôme Fayette, et al.. (2017). Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.. Journal of Clinical Oncology. 35(15_suppl). 6020–6020. 14 indexed citations

Kiyota, Naomi, Yasuhisa Hasegawa, Shunji Takahashi, et al.. (2017). A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncology. 73. 138–146. 72 indexed citations

10.

Chi, Alexander, Sijin Wen, Manish Monga, et al.. (2016). Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer. PLoS ONE. 11(9). e0162453–e0162453. 3 indexed citations

11.

Haddad, Robert I., Maura L. Gillison, Robert L. Ferris, et al.. (2016). Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714. Annals of Oncology. 27. vi350–vi350. 5 indexed citations

12.

Belani, Chandra P., Suzanne E. Dahlberg, Charles M. Rudin, et al.. (2016). Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive‐stage small cell lung cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E1508). Cancer. 122(15). 2371–2378. 61 indexed citations

13.

Chi, Alexander, Sijin Wen, Manish Monga, et al.. (2016). Chest wall dose assessment in stereotactic ablative radiotherapy delivered with volumetric modulated arc therapy for peripheral lung tumors. Cancer Treatment and Research Communications. 9. 5–14. 3 indexed citations

14.

Monga, Manish, et al.. (2014). Sorafenib and thyroid cancer. Expert Review of Endocrinology & Metabolism. 9(6). 561–570. 33 indexed citations

15.

Chi, Alexander, Nam P. Nguyen, James S. Welsh, et al.. (2014). Strategies of Dose Escalation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer: Image Guidance and Beyond. Frontiers in Oncology. 4. 156–156. 11 indexed citations

16.

Figg, William D., Manish Monga, Donna Headlee, et al.. (2014). A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. Cancer Chemotherapy and Pharmacology. 74(5). 955–967. 15 indexed citations

17.

Shah, Nilay, Farhad Khimani, Michael Newton, et al.. (2014). Metformin use and survival in diabetic patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology. 32(15_suppl). e15612–e15612. 3 indexed citations

18.

Remick, Scot C., et al.. (2013). Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies. Clinical & Experimental Metastasis. 31(2). 257–267. 9 indexed citations

19.

Monga, Manish & E. A. Sausville. (2003). Developmental Therapeutics Program at the NCI: Molecular Target and Drug Discovery Process. ChemInform. 34(8). 6 indexed citations

20.

Monga, Manish, et al.. (2002). Developmental Therapeutics Program at the NCI: molecular target and drug discovery process. Leukemia. 16(4). 520–526. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact